Cargando…

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy

Purpose: Triple-negative breast cancer (TNBC) is a subtype with distinct heterogeneity, high invasiveness, and poorer prognosis. There is a controversy about adjuvant chemotherapy (ACT) at the T1aN0M0 stage. This study was carried out to assess the survival benefit of ACT for these patients. Methods...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Wen-Fen, Chen, Qing-Xia, Wang, Xiao-Xiao, Zhang, Jie, Song, Chuan-Gui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556218/ https://www.ncbi.nlm.nih.gov/pubmed/33102205 http://dx.doi.org/10.3389/fonc.2020.01753

Ejemplares similares

Is Adjuvant Chemotherapy Beneficial to All Patients With pT3N0M0 Stage Gastric Cancer?
por: Huang, Jiao-Bao, et al.
Publicado: (2021)

Nomogram for Predicting Overall Survival and Assessing the Survival Benefit of Adjuvant Treatment in pT1-2N0M0 Triple-Negative Breast Cancer: A Surveillance, Epidemiology, and End Results-Based Study
por: Mao, Qixin, et al.
Publicado: (2022)

Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer
por: Zhai, Zhen, et al.
Publicado: (2020)

Optimal Surgery Type and Adjuvant Therapy for T1N0M0 Lung Large Cell Neuroendocrine Carcinoma
por: Peng, Kunwei, et al.
Publicado: (2021)

Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis
por: Kuo, Yu-Hsuan, et al.
Publicado: (2022)

Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection
por: Li, Xiao-hui, et al.
Publicado: (2022)

Comparison of T2N0M0 and T3aN0M0 in Predicting the Prognosis of Patients With Renal Cell Carcinoma
por: He, Xiaobo, et al.
Publicado: (2020)

Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis
por: Wu, Chenghui, et al.
Publicado: (2023)

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2023)

Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population
por: Lim, SeungTaek, et al.
Publicado: (2015)

Indication for and Effect of Adjuvant Chemotherapy for Stage IIa (T3N0M0) Colon Cancer
por: Jeon, Chul-Hyo, et al.
Publicado: (2019)

Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database
por: Wu, Junzhao, et al.
Publicado: (2022)

The Survival Effect of Chest Wall With or Without Regional Lymphatic Radiotherapy for Breast Cancer Patients With T3~4N0M0
por: Li, Guanqiao, et al.
Publicado: (2021)

Risk Factors for Pathologically Confirmed Lymph Nodes Metastasis in Patients With Clinical T2N0M0 Stage Prostate Cancer
por: Xu, Ning, et al.
Publicado: (2020)

Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer
por: Wang, Qi-Wei, et al.
Publicado: (2018)

The role of chemotherapy in patients with T1bN0M0 triple-negative breast cancer: a real-world competing risk analysis
por: Lan, Tian, et al.
Publicado: (2021)

Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
por: Kim, Hyun-Ah, et al.
Publicado: (2015)

Efficacy, safety, and controversy of ultrasound-guided radiofrequency ablation in the treatment of T1N0M0 papillary thyroid carcinoma
por: Yi, Zhang, et al.
Publicado: (2022)

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
por: Shi, Jinming, et al.
Publicado: (2022)

Adjuvant Chemotherapy in pT2N0M0 Gastric Cancer: Findings From a Retrospective Study
por: Mei, Yu, et al.
Publicado: (2022)

Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer—an east and west multicenter study
por: Huang, Ze-Ning, et al.
Publicado: (2019)

Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer
por: Xia, Lin-Yu, et al.
Publicado: (2022)

Prognostic analysis of pT1-T2aN0M0 cervical adenocarcinoma based on random survival forest analysis and the generation of a predictive nomogram
por: Ouyang, Dong, et al.
Publicado: (2022)

Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
por: Xia, Lin-Yu, et al.
Publicado: (2020)

Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0
por: You, Kai-yun, et al.
Publicado: (2014)

Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort
por: Shen, Kaiwen, et al.
Publicado: (2022)

A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Zhu, Meizhen, et al.
Publicado: (2021)

Survival benefit of perioperative chemotherapy for T1–3N0M0 stage esophageal cancer: a SEER database analysis
por: Shao, Yue, et al.
Publicado: (2021)

Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer
por: Morante, Zaida, et al.
Publicado: (2023)

Value of N1 Lymph Node Examination in the Prognosis of Patients With pT1-3N0M0 Non-Small Cell Lung Cancer
por: Wang, Gaoxiang, et al.
Publicado: (2020)

Radiotherapy Versus Surgery–Which Is Better for Patients With T1-2N0M0 Glottic Laryngeal Squamous Cell Carcinoma? Individualized Survival Prediction Based on Web-Based Nomograms
por: Du, Yajing, et al.
Publicado: (2020)

Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data
por: Xu, Cheng, et al.
Publicado: (2019)

Development and validation of nomogram prognostic model for early-stage T1-2N0M0 small cell lung cancer: A population-based analysis
por: Ge, Tao, et al.
Publicado: (2022)

Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice
por: Xiu, Meng, et al.
Publicado: (2022)

Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy
por: Shao, Xinxin, et al.
Publicado: (2023)

Association of survival with adjuvant radiotherapy for pN0 esophageal cancer
por: Gao, Huijiang, et al.
Publicado: (2023)

Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?
por: Hou, X., et al.
Publicado: (2022)

Cause-Specific Mortality Among Survivors From T1N0M0 Renal Cell Carcinoma: A Registry-Based Cohort Study
por: Wang, Zhixian, et al.
Publicado: (2021)

The Prognostic Impact of Tumor Location in pT3N0M0 Upper Urinary Tract Urothelial Carcinoma: A Retrospective Cohort Study
por: Chen, Tzu Shuang, et al.
Publicado: (2022)

Prognostic Nomogram Based on the Metastatic Lymph Node Ratio for T(1-4)N(0-1)M(0) Pancreatic Neuroendocrine Tumors After Surgery
por: Shi, Jingxiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b8lkkik1km8ef3t0bq9oe0s8k5